Search | IOVS | ARVO Journals

Showing 1 – 20 of 25

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

PER-001 Ocular Tissue Distribution and Duration of Release Following Intravitreal Administration of PER-001 Sustained Release Intravitreal Implants in Rabbits

Angie Glendenning; Maria Zaretskaia; Heather Schmitt; Karen E. Brennan; Chris Romeo; Pratap Challa; Cheng-Wen Lin; Sevgi Gurkan

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):199.

ARVO Annual Meeting Abstract June 2024

Ocular and systemic safety of PER-001 Intravitreal Implant after single administration in rabbits and monkeys

Maria Zaretskaia; Angela Glendenning; Karen E. Brennan; Heather Schmitt; Chris Romeo; Andrew Melie; Michelle Chen; Phillip Lai; Cheng-Wen Lin; Sevgi Gurkan

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):198.

ARVO Annual Meeting Abstract June 2024

An Endothelin-1 receptor antagonist PER-001 improved maladaptive neovascularization at equal efficacy as aflibercept in an oxygen-induced retinopathy mouse model.

Heather Schmitt; Maria Zaretskaia; Angela Glendenning; Chris Romeo; Cheng-Wen Lin; Sevgi Gurkan

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):196.

ARVO Annual Meeting Abstract June 2024

A Phase IIa Study of A Novel Non-Invasive Treatment, TO-O-1002, in nAMD Patients

Cheng-Wen Lin; Thuss Sanguansak; Duangnate Rojanaporn; Kanin Luangsawang; Wongsiri Taweebanjongsin

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1935.

ARVO Annual Meeting Abstract June 2021

Novel corticosteroid class reduces inflammation and lowers IOP in animal models

Kevin Carbajal; Maria V. Zaretskaia; Cyndi L. Lichorowic; Jill M. Sturdivant; Meredith Weksler; Alan McDougal; Cheng-Wen Lin; Mitchell A. deLong; Casey Kopczynski; David A. Hollander; Jeff White

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1302.

ARVO Annual Meeting Abstract June 2021

Ocular pharmacokinetics of a novel class of corticosteroids with ROCK inhibitory activity and potential for reduced steroid-associated risks

Maria V. Zaretskaia; Kevin Carbajal; Cyndi L. Lichorowic; Jill M. Sturdivant; Monica Germann; Christopher Romeo; Karen Crews; Angie Glendenning; Meredith Weksler; Alan McDougal; Mitchell A. deLong; Cheng-Wen Lin; Casey Kopczynski; David A. Hollander; Jeff White

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1292.

ARVO Annual Meeting Abstract June 2020

A novel corticosteroid with ROCK inhibitory activity can reduce ocular inflammation and lower IOP in animal models

Kevin Carbajal; Maria V. Zaretskaia; Cyndi Lichorowic; Jill M. Sturdivant; Eric C Carlson; Monica Germann; Karen Crews; Meredith Weksler; Alan McDougal; Mitchell A. deLong; Casey Kopczynski; Cheng-Wen Lin

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2953.

ARVO Annual Meeting Abstract June 2020

Novel corticosteroids with inhibitory activity against ROCK reach target ocular tissues and reduce inflammation in EIU

Maria V Zaretskaia; Kevin Carbajal; Cyndi Lichorowic; Jill M. Sturdivant; Eric C Carlson; Monica Germann; Karen Crews; Meredith Weksler; Alan McDougal; Mitchell A. deLong; Casey Kopczynski; Cheng-Wen Lin

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2983.

ARVO Annual Meeting Abstract June 2020

Small-molecule JAK/IKK Kinase Inhibitors and JAK/ROCK/IKK Inhibitors for Treatment of Posterior Segment Disease via a Sustained Release PEA Bioerodible Implant.

Mitchell A. deLong; Briana Foley; Kyle Vick; Daphne Clancy; Steve Miller; Curtis Kelly; Jill M. Sturdivant; Cyndi Lichorowic; Cheng-Wen Lin; Casey Kopczynski

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4922.

ARVO Annual Meeting Abstract July 2019

In vivo measurement of TM stiffness: proof-of-principle in mice

C Ross Ethier; Guorong Li; Chanyoung Lee; Ke Wang; Iris D Navarro; Joseph M Sherwood; Karen Crews; Sina Farsiu; Cheng-Wen Lin; W Daniel Stamer

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5213.

ARVO Annual Meeting Abstract July 2019

Anti-inflammatory Activity of a New Class of JAK/ROCK Inhibitors for Posterior Segment Disease

Mitchell A. deLong; Kyle Vick; jill Sturdivant; Casey Kopczynski; Cheng-Wen Lin

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5381.

ARVO Annual Meeting Abstract July 2019

Ocular Tissue Distribution and Duration of Release of AR-13503 Following Administration of AR-13503 Sustained Release Intravitreal Implant in Rabbits and Miniature Swine

Jindong Ding; Karen Crews; Kevin Carbajal; Meredith Weksler; Lori Moore; Eric C Carlson; Cheng-Wen Lin

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5387.

ARVO Annual Meeting Abstract July 2019

Ocular Pharmacokinetics of a Novel Class of Selective Multi-Kinase Inhibitors with Anti-Inflammatory Potential

Kevin Carbajal; Karen Crews; Kyle Vick; Briana E Foley; Jindong Ding; Angie Glendenning; Meredith Weksler; Cynthia L Lichorowic; Jill Sturdivant; Mitchell A. deLong; Eric C Carlson; Cheng-Wen Lin

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):250.

ARVO Annual Meeting Abstract July 2018

AR-13503 Enhances the Efficacy of Aflibercept in a Mouse Model of Proliferative Diabetic Retinopathy

Kevin Carbajal; Meredith Weksler; Lori Moore; Jindong Ding; Casey Kopczynski; Cheng-Wen Lin

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):200.

ARVO Annual Meeting Abstract July 2018

ROCK/PKC Inhibitor AR-13503 Inhibits Angiogenesis and Protects the Barrier Function of Retinal Pigment Epithelium

Jindong Ding; Briana E Foley; Casey Kopczynski; Cheng-Wen Lin

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):205.

ARVO Annual Meeting Abstract July 2018

Effect of Ring Size on the Suitability of a New Class of Rho Kinase Compounds for Posterior Segment Disease

Mitchell A deLong; Jill Sturdivant; Cynthia Lichorowic; Cheng-Wen Lin; Casey Kopczynski

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):217.

ARVO Annual Meeting Abstract July 2018

Sustained Release, Biodegradable PEA Implants for Intravitreal Delivery of the ROCK/PKC Inhibitor AR-13503

Angela Glendenning; Karen Crews; Jill Sturdivant; Mitchell A deLong; Casey Kopczynski; Cheng-Wen Lin

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5672.

ARVO Annual Meeting Abstract July 2018

Evaluation of the Potential of AR-13324 and AR-13503 to Induce Phospholipidosis

Cheng-Wen Lin; Briana E Foley; Kevin Carbajal; Casey Kopczynski

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):6125.

ARVO Annual Meeting Abstract June 2017

ROCK Inhibitors AR-13324 and AR-13154(S) Block Choroidal Angiogenesis and Protect the Barrier Function of Retinal Pigment Epithelium

Jindong Ding; Kevin Carbajal; Casey Kopczynski; Cheng-Wen Lin

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1967.

ARVO Annual Meeting Abstract June 2017

Therapeutic Potential of Sustained Delivery of AR-13154(S) in an Animal Model of Proliferative Diabetic Retinopathy

Kevin Carbajal; Jindong Ding; Meredith Weksler; Lori Moore; Casey Kopczynski; Cheng-Wen Lin

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1977.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Specify Date Range

PER-001 Ocular Tissue Distribution and Duration of Release Following Intravitreal Administration of PER-001 Sustained Release Intravitreal Implants in Rabbits

Ocular and systemic safety of PER-001 Intravitreal Implant after single administration in rabbits and monkeys

An Endothelin-1 receptor antagonist PER-001 improved maladaptive neovascularization at equal efficacy as aflibercept in an oxygen-induced retinopathy mouse model.

A Phase IIa Study of A Novel Non-Invasive Treatment, TO-O-1002, in nAMD Patients

Novel corticosteroid class reduces inflammation and lowers IOP in animal models

Ocular pharmacokinetics of a novel class of corticosteroids with ROCK inhibitory activity and potential for reduced steroid-associated risks

A novel corticosteroid with ROCK inhibitory activity can reduce ocular inflammation and lower IOP in animal models

Novel corticosteroids with inhibitory activity against ROCK reach target ocular tissues and reduce inflammation in EIU

Small-molecule JAK/IKK Kinase Inhibitors and JAK/ROCK/IKK Inhibitors for Treatment of Posterior Segment Disease via a Sustained Release PEA Bioerodible Implant.

In vivo measurement of TM stiffness: proof-of-principle in mice

Anti-inflammatory Activity of a New Class of JAK/ROCK Inhibitors for Posterior Segment Disease

Ocular Tissue Distribution and Duration of Release of AR-13503 Following Administration of AR-13503 Sustained Release Intravitreal Implant in Rabbits and Miniature Swine

Ocular Pharmacokinetics of a Novel Class of Selective Multi-Kinase Inhibitors with Anti-Inflammatory Potential

AR-13503 Enhances the Efficacy of Aflibercept in a Mouse Model of Proliferative Diabetic Retinopathy

ROCK/PKC Inhibitor AR-13503 Inhibits Angiogenesis and Protects the Barrier Function of Retinal Pigment Epithelium

Effect of Ring Size on the Suitability of a New Class of Rho Kinase Compounds for Posterior Segment Disease

Sustained Release, Biodegradable PEA Implants for Intravitreal Delivery of the ROCK/PKC Inhibitor AR-13503

Evaluation of the Potential of AR-13324 and AR-13503 to Induce Phospholipidosis

ROCK Inhibitors AR-13324 and AR-13154(S) Block Choroidal Angiogenesis and Protect the Barrier Function of Retinal Pigment Epithelium

Therapeutic Potential of Sustained Delivery of AR-13154(S) in an Animal Model of Proliferative Diabetic Retinopathy

To View More...

You must be signed into an individual account to use this feature.